<div>
  <p>
  </p>
  <ul>
    <li>
      <p>
        Genetic testing, CDx, and PGx company Myriad Genetics has acquired specific assets from Intermountain Precision Genomics (IPG)'s laboratory business, a subsidiary of Intermountain Health. The assets include the Precise Tumor Test, Precise Liquid Test, and IPG's CLIA-certified laboratory in Utah.
      </p>
    </li>
    <li>
      <p>
        The Precise Tumor Test by Myriad examines a patient's tumor DNA to identify and address significant variants present within tumors. The Precise Liquid Test, expected to be launched later this year, is claimed to offer convenient and thorough genomic profiling results obtained from a blood sample. IPG has concluded all validation studies necessary to support the local coverage determination for Precise Liquid.
      </p>
    </li>
    <li>
      <p>
        The acquisition is expected to enable Myriad to expand its tumor profiling services, which complement its existing oncology portfolio of hereditary cancer and companion diagnostic testing options.
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.utahbusiness.com/myriad-genetics-acquires-precise-tumor/">
      Utah business
    </a>
  </p>
</div>


Precision Medicine

<div>
 
 <p>Myriad Genetics, a company specializing in genetic testing, CDx, and PGx, has purchased certain assets from Intermountain Precision Genomics (IPG)'s laboratory business. IPG, a subsidiary of Intermountain Health, had developed notable assets such as the Precise Tumor Test, Precise Liquid Test, and a CLIA-certified laboratory located in Utah, all of which are now under Myriad's ownership.</p> 
 <p>Myriad's Precise Tumor Test involves studying a patient's tumor DNA to detect and deal with significant variants within these tumors. Myriad plans to launch the Precise Liquid Test, a service that gives comprehensive genomic profiling results from a blood sample later in the year. Deducingly, IPG has completed all necessary validation studies needed to back the local coverage choice for Precise Liquid.</p>
 <p>This acquisition is predicted to facilitate Myriad's expansion in the sphere of tumor profiling services. This development will supplement Myriad's existing operations in hereditary cancer and companion diagnostic testing.</p>
 
</div>

Myriad Genetics acquires select assets from Intermountain Health to enhance oncology portfolio

<div>
 
 <p>Myriad Genetics, a molecular diagnostic company, is set to acquire select assets from Intermountain Precision Genomics' (IPG) laboratory business to strengthen its oncology portfolio. The acquisition, scheduled to close on February 1, 2024, will include IPG's key products: The Precise Tumor Test and the upcoming Precise Liquid Test. Additionally, Myriad Genetics will acquire IPG's Certified laboratory in Utah, U.S. The acquisition aims to create operational efficiencies, enhance reimbursement benefits and boost opportunities for clinical development.</p>
  
</div>

Myriad Genetics acquires select assets from Intermountain Precision Genomics to expand oncology portfolio

Myriad Genetics and Onsite Women’s Health partner to launch breast cancer risk assessment program

All Updates

Myriad Genetics acquires select assets from Intermountain Health to enhance oncology portfolio

Myriad Genetics acquires select assets from Intermountain Precision Genomics to expand oncology portfolio

Myriad Genetics and Onsite Women’s Health partner to launch breast cancer risk assessment program

Myriad Genetics reports Q2 2023 financial results; net losses deepen

Myriad Genetics launches breast cancer risk test with breast density integration and polygenic risk score

Myriad Genetics secures USD 90 million credit facility

Myriad Genetics and MD Anderson partner to use minimal residual disease platform

Myriad Genetics reports Q1 2023 financial results; revises FY 2023 guidance

Illumina and Myriad Genetics expand partnership to bring HRD testing to the US

Myriad Genetics misses Q4 2022 analyst expectations; losses widen